Nasdaq · CIK 0001625297
INDV Indivior Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing Mar 17, 2026. Close $35.83 on Oct 9, 2026, +51% from the 52-week low and -14% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
13
with a Form 4 at this company
Price and insider trades, last year
INDVOct 9, 2026 · close 35.83
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Indivior Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | Barbara Ryan director buy | $249 8 shares | +0% | - | |
| 34Weak | Stuart A Kingsley director buy | $30k 940 shares | +20% | - | |
| 23Weak | Barbara Ryan director buy | $1,009 31 shares | +1% | - | |
| 23Weak | Keith Humphreys director buy | $27k 775 shares | +15% | - | |
| 20Weak | Daniel A Ninivaggi director buy | $27k 775 shares | +5% | - | |
| 20Weak | Mark Stejbach director buy | $27k 775 shares | +5% | - | |
| 26Weak | David E. Wheadon director buy | $63k 1,771 shares | +14% | - | |
| 30Weak | Barbara Ryan director buy | $27k 775 shares | +65% | - |
Transactions
The last 43 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 14, 2026 | Ryan Preblick Chief Financial Officer | MOption exercise Common Stock | +6,302 | - | - | 323,594 | Mar 17, 2026 |
| Mar 14, 2026 | Ryan Preblick Chief Financial Officer | FTax withholding Common Stock | -2,843 | $31.11 | $88k | 320,751 | Mar 17, 2026 |
| Mar 14, 2026 | Ryan Preblick Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -6,302 | - | - | 0 | Mar 17, 2026 |
| Mar 13, 2026 | Barbara Ryan director | POpen-market purchase Common Stock | +8 | $31.09 | $249 | 5,724 | Mar 13, 2026 |
| Mar 9, 2026 | Barbara Ryan director | POpen-market purchase Common Stock | +31 | $32.56 | $1,009 | 5,716 | Mar 11, 2026 |
| Mar 6, 2026 | Stuart A Kingsley director | POpen-market purchase Common Stock | +940 | $31.87 | $30k | 5,582 | Mar 11, 2026 |
| Mar 3, 2026 | Jeffrey W Burris Chief Legal Officer | MOption exercise Common Stock | +79,893 | - | - | 107,550 | Mar 5, 2026 |
| Mar 3, 2026 | Ryan Preblick Chief Financial Officer | FTax withholding Common Stock | -87,597 | $31.98 | $2.8M | 230,343 | Mar 5, 2026 |
| Mar 3, 2026 | Christian Heidbreder Chief Scientific Officer | MOption exercise Common Stock | +101,544 | - | - | 292,306 | Mar 5, 2026 |
| Mar 3, 2026 | Woodrow D Anderson Chief Accounting Officer | MOption exercise Common Stock | +18,364 | - | - | 29,657 | Mar 5, 2026 |
| Mar 3, 2026 | Jeffrey W Burris Chief Legal Officer | FTax withholding Common Stock | -36,032 | $31.98 | $1.2M | 71,518 | Mar 5, 2026 |
| Mar 3, 2026 | Christian Heidbreder Chief Scientific Officer | FTax withholding Common Stock | -45,797 | $31.98 | $1.5M | 246,509 | Mar 5, 2026 |
| Mar 3, 2026 | Woodrow D Anderson Chief Accounting Officer | FTax withholding Common Stock | -8,283 | $31.98 | $265k | 21,374 | Mar 5, 2026 |
| Mar 3, 2026 | Ryan Preblick Chief Financial Officer | MOption exercise Common Stock | +86,949 | - | - | 317,292 | Mar 5, 2026 |
| Mar 3, 2026 | Jeffrey W Burris Chief Legal Officer | MOption exercise Performance Stock Unitsderivative | -104,300 | - | - | 0 | Mar 5, 2026 |
| Mar 3, 2026 | Woodrow D Anderson Chief Accounting Officer | MOption exercise Common Stock | +5,946 | - | - | 27,320 | Mar 5, 2026 |
| Mar 3, 2026 | Christian Heidbreder Chief Scientific Officer | MOption exercise Performance Stock Unitsderivative | -132,565 | - | - | 0 | Mar 5, 2026 |
| Mar 3, 2026 | Ryan Preblick Chief Financial Officer | MOption exercise Performance Stock Unitsderivative | -113,510 | - | - | 0 | Mar 5, 2026 |
| Mar 3, 2026 | Woodrow D Anderson Chief Accounting Officer | FTax withholding Common Stock | -2,682 | $31.98 | $86k | 24,638 | Mar 5, 2026 |
| Mar 3, 2026 | Woodrow D Anderson Chief Accounting Officer | MOption exercise Performance Stock Unitsderivative | -23,975 | - | - | 0 | Mar 5, 2026 |
| Mar 3, 2026 | Woodrow D Anderson Chief Accounting Officer | MOption exercise Restricted Stock Unitsderivative | -5,946 | - | - | 0 | Mar 5, 2026 |
| Feb 10, 2026 | Woodrow D Anderson Chief Accounting Officer | AGrant or award Common Stock | +6,903 | $0.00 | $0 | 11,293 | Feb 12, 2026 |
| Feb 10, 2026 | Ryan Preblick Chief Financial Officer | AGrant or award Common Stock | +37,358 | $0.00 | $0 | 317,940 | Feb 12, 2026 |
| Feb 10, 2026 | Christian Heidbreder Chief Scientific Officer | AGrant or award Common Stock | +33,622 | $0.00 | $0 | 190,762 | Feb 12, 2026 |
| Feb 10, 2026 | Jeffrey W Burris Chief Legal Officer | AGrant or award Common Stock | +26,897 | $0.00 | $0 | 27,657 | Feb 12, 2026 |
| Feb 10, 2026 | Patrick A Barry Chief Commercial Officer | AGrant or award Common Stock | +31,380 | $0.00 | $0 | 31,380 | Feb 12, 2026 |
| Feb 10, 2026 | Joseph Ciaffoni Chief Executive Officer | AGrant or award Common Stock | +79,976 | $0.00 | $0 | 135,976 | Feb 12, 2026 |
| Feb 9, 2026 | Woodrow D Anderson Chief Accounting Officer | AGrant or award Performance Stock Unitsderivative | +23,975 | $0.00 | $0 | 23,975 | Feb 12, 2026 |
| Feb 9, 2026 | Jeffrey W Burris Chief Legal Officer | AGrant or award Performance Stock Unitsderivative | +104,300 | $0.00 | $0 | 104,300 | Feb 12, 2026 |
| Feb 9, 2026 | Christian Heidbreder Chief Scientific Officer | AGrant or award Performance Stock Unitsderivative | +132,565 | $0.00 | $0 | 132,565 | Feb 12, 2026 |
| Feb 9, 2026 | Ryan Preblick Chief Financial Officer | AGrant or award Performance Stock Unitsderivative | +113,510 | $0.00 | $0 | 113,510 | Feb 12, 2026 |
| Jan 26, 2026 | Stuart A Kingsley director | AGrant or award Common Stock | +3,722 | $0.00 | $0 | 4,642 | Jan 28, 2026 |
| Jan 26, 2026 | Barbara Ryan director | AGrant or award Common Stock | +3,722 | $0.00 | $0 | 5,685 | Jan 28, 2026 |
| Jan 26, 2026 | David E. Wheadon director | AGrant or award Common Stock | +5,955 | $0.00 | $0 | 20,350 | Jan 28, 2026 |
| Jan 26, 2026 | Juliet Thompson director | AGrant or award Common Stock | +3,722 | $0.00 | $0 | 7,572 | Jan 28, 2026 |
| Jan 26, 2026 | Mark Stejbach director | AGrant or award Common Stock | +3,722 | $0.00 | $0 | 20,569 | Jan 28, 2026 |
| Jan 26, 2026 | Daniel A Ninivaggi director | AGrant or award Common Stock | +3,722 | $0.00 | $0 | 20,645 | Jan 28, 2026 |
| Jan 26, 2026 | Keith Humphreys director | AGrant or award Common Stock | +3,722 | $0.00 | $0 | 9,524 | Jan 28, 2026 |
| Jan 5, 2026 | Keith Humphreys director | POpen-market purchase Ordinary Shares10b5-1 | +775 | $35.39 | $27k | 5,802 | Jan 7, 2026 |
| Jan 5, 2026 | Daniel A Ninivaggi director | POpen-market purchase Ordinary Shares10b5-1 | +775 | $35.39 | $27k | 16,923 | Jan 7, 2026 |
| Jan 5, 2026 | Mark Stejbach director | POpen-market purchase Ordinary Shares10b5-1 | +775 | $35.39 | $27k | 16,847 | Jan 7, 2026 |
| Jan 5, 2026 | David E. Wheadon director | POpen-market purchase Ordinary Shares10b5-1 | +1,771 | $35.39 | $63k | 14,395 | Jan 7, 2026 |
| Jan 5, 2026 | Barbara Ryan director | POpen-market purchase Ordinary Shares10b5-1 | +775 | $35.39 | $27k | 1,963 | Jan 7, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Woodrow D AndersonChief Accounting Officer
- Patrick A BarryChief Commercial Officer
- Jeffrey W BurrisChief Legal Officer
- Joseph CiaffoniChief Executive Officer
- Christian HeidbrederChief Scientific Officer
- Keith Humphreysdirector
- Stuart A Kingsleydirector
- Daniel A Ninivaggidirector
- Ryan PreblickChief Financial Officer
- Barbara Ryandirector
- Mark Stejbachdirector
- Juliet Thompsondirector
- David E. Wheadondirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.